Serotonergic mechanisms in Parkinson's Disease: Opposing results from preclinical and clinical data.

B. Scholtissen; F.R.J. Verhey; H.W.M. Steinbusch; A.F.G. Leentjens

doi:10.1007/s00702-005-0368-3

Serotonergic mechanisms in Parkinson's Disease: Opposing results from preclinical and clinical data.

B. Scholtissen^*, F.R.J. Verhey, H.W.M. Steinbusch, A.F.G. Leentjens

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Parkinson's disease (PD) is a neuropsychiatric disease affecting approximately 1-2% of the general population. The classical triad of symptoms, tremor, rigidity, and bradykinesia is mainly caused by degeneration of dopaminergic neurons from the substantia nigra. However, other neurotransmitter systems also show signs of degeneration, among which the serotonergic system. The exact role of serotonin in PD remains unclear. We present here a review about functional serotonergic interventions and serotonergic imaging studies in PD, and will go into the importance of combining preclinical and clinical research data in order to gain more insight into the role of serotonin in PD. More specifically, the present review is aimed at bridging the gap between data from animal models of PD and data from human research.

Original language	English
Pages (from-to)	59-73
Journal	Journal of Neural Transmission
Volume	113
Issue number	1
DOIs	https://doi.org/10.1007/s00702-005-0368-3
Publication status	Published - 1 Jan 2006

Access to Document

10.1007/s00702-005-0368-3

Cite this

@article{f6fe18c4bfff4c9181bd5644f89e272e,

title = "Serotonergic mechanisms in Parkinson's Disease: Opposing results from preclinical and clinical data.",

abstract = "Parkinson's disease (PD) is a neuropsychiatric disease affecting approximately 1-2% of the general population. The classical triad of symptoms, tremor, rigidity, and bradykinesia is mainly caused by degeneration of dopaminergic neurons from the substantia nigra. However, other neurotransmitter systems also show signs of degeneration, among which the serotonergic system. The exact role of serotonin in PD remains unclear. We present here a review about functional serotonergic interventions and serotonergic imaging studies in PD, and will go into the importance of combining preclinical and clinical research data in order to gain more insight into the role of serotonin in PD. More specifically, the present review is aimed at bridging the gap between data from animal models of PD and data from human research.",

author = "B. Scholtissen and F.R.J. Verhey and H.W.M. Steinbusch and A.F.G. Leentjens",

year = "2006",

month = jan,

day = "1",

doi = "10.1007/s00702-005-0368-3",

language = "English",

volume = "113",

pages = "59--73",

journal = "Journal of Neural Transmission",

issn = "0300-9564",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Serotonergic mechanisms in Parkinson's Disease: Opposing results from preclinical and clinical data.

AU - Scholtissen, B.

AU - Verhey, F.R.J.

AU - Steinbusch, H.W.M.

AU - Leentjens, A.F.G.

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Parkinson's disease (PD) is a neuropsychiatric disease affecting approximately 1-2% of the general population. The classical triad of symptoms, tremor, rigidity, and bradykinesia is mainly caused by degeneration of dopaminergic neurons from the substantia nigra. However, other neurotransmitter systems also show signs of degeneration, among which the serotonergic system. The exact role of serotonin in PD remains unclear. We present here a review about functional serotonergic interventions and serotonergic imaging studies in PD, and will go into the importance of combining preclinical and clinical research data in order to gain more insight into the role of serotonin in PD. More specifically, the present review is aimed at bridging the gap between data from animal models of PD and data from human research.

AB - Parkinson's disease (PD) is a neuropsychiatric disease affecting approximately 1-2% of the general population. The classical triad of symptoms, tremor, rigidity, and bradykinesia is mainly caused by degeneration of dopaminergic neurons from the substantia nigra. However, other neurotransmitter systems also show signs of degeneration, among which the serotonergic system. The exact role of serotonin in PD remains unclear. We present here a review about functional serotonergic interventions and serotonergic imaging studies in PD, and will go into the importance of combining preclinical and clinical research data in order to gain more insight into the role of serotonin in PD. More specifically, the present review is aimed at bridging the gap between data from animal models of PD and data from human research.

U2 - 10.1007/s00702-005-0368-3

DO - 10.1007/s00702-005-0368-3

M3 - Article

SN - 0300-9564

VL - 113

SP - 59

EP - 73

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

IS - 1

ER -